Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].

Zhonghua nei ke za zhi - 1 Jun 2023

He F, Li T, Li Y F, Tang P, Sang L N, Huang Y M, Sun L, Liu L

Abstract excerpt

Objective: To exploring the clinical features of SF3B1-mutated myelodysplastic syndrome with excess blasts (MDS-EB) and analyzing the association between SF3B1 mutation, and efficacy and prognostic significance for patients with MDS-EB. Methods: This was a retrospective case series study. The clinical data of 266 patients with MDS-EB diagnosed in the First Affiliated Hospital of Zhengzhou University between April...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over
Share to Leukocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Phosphoproteins

Share to Prognosis

Share to RNA Splicing Factors

Share to Young Adult

Source

Identifiers

PMID: 37263951
DOI: 10.3760/cma.j.cn112138-20220902-00650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].PMID 37263951Read ↗

[Clinical Characteristics and Prognosis Analysis of MDS-RS Patients with Wild-Type SF3B1].Semantic proximity Read ↗

Myelodysplastic Syndrome Updated.Semantic proximity Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

[New insights into the nature and classification of myelodysplastic neopmasm].Semantic proximity Read ↗

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease processSemantic proximity Read ↗

[Clinical characteristics and prognosis of myelodysplastic neoplasms with GATA2 mutations].Semantic proximity Read ↗

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Semantic proximity Read ↗

[Risk factors for leukemia transformation in patients with myelodysplastic syndromes].Semantic proximity Read ↗

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment.Semantic proximity Read ↗

Significance of SF3B1 Mutations in Myeloid Neoplasms.Semantic proximity Read ↗

[Clinical Characteristics and Prognosis of Myelodysplastic Syndromes Patients with RUNX1 Gene Mutation].Semantic proximity Read ↗

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.